Summary

Apremilast, an oral phosphodiesterase 4 inhibitor that works intracellularly to regulate inflammatory mediators, has been tested in the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) program, which consists of 2 trials: ESTEEM 1 [NCT01194219] and ESTEEM 2 [NCT01232283]. This article presents the 52-week results of the ESTEEM 2 trial.